DRMAW (STOCKS)

    Dermata Therapeutics, Inc. Warrant

    $0.017500
    +0.000000 (+0.00%)
    Prev close: $0.017500
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals Major
    CEO
    Gerry Proehl, MBA
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    Employees
    8
    P/E (TTM)
    P/B (TTM)
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Dec 2025)
    Revenues $0.00
    Operating Expenses $7.77M
    Selling, General, and Administrative Expenses $4.84M
    Research and Development $2.93M
    Operating Income/Loss -$7.77M
    Income/Loss From Continuing Operations After Tax -$7.56M
    Income/Loss From Continuing Operations Before Tax -$7.56M
    Net Income/Loss -$7.56M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$7.56M
    Net Income/Loss Available To Common Stockholders, Basic -$7.56M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$8.16
    Diluted Earnings Per Share -$8.16
    Basic Average Shares 926,192
    Diluted Average Shares 926,192
    Assets $7.86M
    Current Assets $7.86M
    Noncurrent Assets $0.00
    Liabilities $1.64M
    Current Liabilities $1.64M
    Accounts Payable $460.81K
    Wages $979.45K
    Other Current Liabilities $200.18K
    Noncurrent Liabilities $0.00
    Equity $6.22M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $6.22M
    Liabilities And Equity $7.86M
    Net Cash Flow From Operating Activities -$7.76M
    Net Cash Flow From Operating Activities, Continuing -$7.76M
    Net Cash Flow From Investing Activities -$4.36M
    Net Cash Flow From Investing Activities, Continuing -$4.36M
    Net Cash Flow From Financing Activities $12.12M
    Net Cash Flow From Financing Activities, Continuing $12.12M
    Net Cash Flow $0.00
    Net Cash Flow, Continuing $0.00
    Comprehensive Income/Loss -$7.56M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$7.56M
    Other Comprehensive Income/Loss $0.00